1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Lyka Labs Limited

Lyka Labs Limited

80.99
INR
-1.65
(-2.00%)
-2.62EPS
2.67BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
55.08
77.05
- -
47.65
21.82
22.54
19.47
23.39
63.99
30.69
31.88
38.37
35.98
38.43
Basic EPS, GAAP
-3.05
-2.29
- -
-2.56
-6.69
-1.95
-21.25
-4.03
13.59
-4.59
-0.75
2.22
-2.81
-2.48
Free Cash Flow per Basic Share
11.49
9.14
- -
8.16
2.81
7.67
1.48
2.63
25
0.27
-2.26
-3.81
-1.65
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
24.43
19.95
- -
16.62
17.58
15.29
-5
-8.99
4.65
14.81
20.6
29.01
25.89
- -
Tangible Book Value per Share
-12.95
-14.47
- -
-9.72
-0.15
-1.57
-20.13
-23.03
-4.45
8.08
17
26.43
24
- -
Basic Weighted Avg Shares
22
22
22
22
26
28
28
29
29
29
33
36
36
36
Sales/Revenue/Turnover
1,189
1,663
- -
1,050
564
642
555
671
1,836
883
1,051
1,385
1,284
1,377
Operating Margin (%)
1.68
10.59
- -
11.92
-26.3
-14.34
-29.57
16.93
45.66
3.11
2.81
8.06
-9.43
-8.1
Depreciation Expense
88
109
- -
103
113
73
80
83
173
141
128
68
85
84
Net Income, GAAP
-66
-49
- -
-55
-173
-56
-605
-116
390
-132
-25
80
-100
-89
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
35.11
- -
- -
28.69
- -
- -
Profit Margin (%)
-5.54
-2.98
- -
-5.27
-30.65
-8.64
-109.12
-17.22
21.24
-14.96
-2.37
5.79
-7.81
-6.46
Working Capital
-900
-936
- -
-1,027
-1,181
-497
-304
-208
-472
116
129
208
94
- -
LT Debt
580
289
- -
349
41
784
1,272
1,509
617
648
431
188
230
- -
Total Equity
560
466
- -
447
528
458
-151
-251
135
457
683
1,036
908
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
36.71
- -
- -
6.1
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
37.55
- -
- -
7.25
- -
- -
Return on Common Equity (%)
-11.01
-10.34
- -
- -
-40.13
-12
- -
- -
- -
-44.95
-4.38
9.33
-10.24
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
259
- -
LT Borrowings
- -
230
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
36
36
Market Capitalization
2,709
1,604
2,673

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
633
- -
Cash, Cash Equivalents & STI
- -
69
- -
Accounts Receivable, Net
- -
350
- -
Inventories
- -
136
- -
Total Current Liabilities
- -
539
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
259
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
34.73%
-12.31%
Free Cash Flow
- -
-58.58%
-57.2%
Net Income, GAAP
- -
-259.92%
-225.21%
Sales/Revenue/Turnover
- -
33.03%
-7.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
301
412
338
334
1,385
2026
330
367
307
280
1,284
2027
423
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.4
0.58
0.75
0.49
2.22
2026
0.25
-0.94
- -
-2.13
-2.81
2027
0.57
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kunal Narendra Gandhi
Full Time Employees
648
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Spencer Building Mumbai MA India 400036
IPO Date
Feb 9, 1995
Website
lykalabs.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Lyka Labs Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India and international markets; its core products include lyophilized injections, liquid injections, dry powder injections, topical preparations such as ointments, creams, lotions, foams, and gels, as well as emollients, topical steroids, antifungal agents, anti-bacterial formulations, acne management products, dermatological formulations, pain killers, anti-aging creams, hair care products, anti-dandruff shampoos, sunscreens, cosmeceuticals, proton pump inhibitors, nutraceuticals, anti-malarials, cephalosporins, bone resorption inhibitors, antibiotics, and corticosteroid hormones, with offerings spanning intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetology, urology, wound care, and anesthesia categories. Incorporated in 1976 and headquartered in Mumbai, India, with manufacturing facilities in Ankleshwar, Gujarat, and an R&D center in Andheri East, Mumbai, the company operates a WHO-GMP and ISO 9001-certified production setup and provides contract manufacturing services along with technical assistance including stability testing and bioequivalence data. Recent developments include the acquisition of Agilis Healthcare Private Limited's animal healthcare business in 2023; the launch of Tofacitinib ointment in fiscal year 2023; the establishment of FertiNova division for gynaecology and assisted reproductive technology in fiscal year 2025; new product launches encompassing lyophilised injections, liquid injections, dry powder injections, and topical ointments, creams, and lotions in 2025; re-appointment of Kunal Gandhi as Managing Director in January 2024; ongoing National Company Law Tribunal proceedings for amalgamation with subsidiary Lyka Exports Limited, with hearings in 2024 and 2025; and redemption of all unlisted 10% cumulative redeemable preference shares in September 2025.